Viatris (VTRS) reported $14.3B in revenue for fiscal 2025, −3.0% year on year. That ranks #389 by revenue among 2853 SEC filers and #41 in Healthcare. It posted a net loss of −$3.5B for the same year. Revenue has grown 3.2% a year on average since 2018 ($11.4B then). The fiscal 2025 balance sheet shows $37.2B in total assets, $1.3B in cash and $12.5B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $14.3B | −3.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $5.0B | −10.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$2.7B | −$2.7B | FY20252025-12-31 |
| Net incomeProfitLoss | −$3.5B | −$2.9B | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $2.3B | +0.6% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $379M | +16.2% | FY20252025-12-31 |
| Total assetsAssets | $37.2B | −10.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | $14.7B | −21.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $1.3B | +80.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $12.5B | −11.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $3.5B | $176M | Open → |
| Q2 20262026-06-30 | $3.8B | −$119M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 150 of 161 companies compared | −24.6% | |
| Operating marginRank 151 of 160 companies compared | −18.6% | |
| R&D as share of revenueRank 58 of 102 companies compared | 6.8% | |
| Cash as share of revenueRank 91 of 160 companies compared | 9.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Viatris Inc
- Ticker
- VTRS
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001792044
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| IQVIA HoldingsIQV | $16.3B | $1.4B |
| Principal FinancialPFG | $15.6B | $1.3B |
| Regeneron PharmaceuticalsREGN | $14.3B | $4.5B |
| ViatrisVTRS | $14.3B | −$3.5B |
| Labcorp HoldingsLH | $14.0B | $877M |
| DavitaDVA | $13.6B | $1.1B |
| Unum GroupUNM | $13.1B | $739M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Viatris — Key figures |url=https://companiesranked.com/en/company/viatris |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Viatris — Key figures. CompaniesRanked. https://companiesranked.com/en/company/viatrisBibTeX
@misc{companiesranked-en-company-viatris-2026,
author = {{CompaniesRanked}},
title = {{Viatris — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/viatris}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001792044-26-000013 · February 26, 2026
{{cite web |title=Viatris — Key figures — 10-K (0001792044-26-000013) |url=https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.